The Canadian Blood Services, Toronto, ON, Canada.
Ann Hematol. 2010 Jul;89 Suppl 1:31-5. doi: 10.1007/s00277-010-0916-2. Epub 2010 Feb 24.
Immune thrombocytopenia (ITP) is an autoimmune disease primarily characterized by increased clearance of auto-antibody-sensitized platelets by Fc-receptor-bearing macrophages in the spleen and liver. It has been classically accepted that antibody-mediated platelet destruction is Fc dependent. Recent studies, however, may also indicate the involvement of Fc-independent pathways of platelet destruction. Current treatment options work by immunosuppression (e.g., corticosteroids), immunomodulation (e.g., IVIg and anti-D), or removal of the platelet destruction site (splenectomy) in ITP. This review will discuss the mechanisms of action of these and other treatments for ITP.
免疫性血小板减少症 (ITP) 是一种自身免疫性疾病，主要特征为脾脏和肝脏中带有 Fc 受体的巨噬细胞清除被自身抗体致敏的血小板。传统上认为抗体介导的血小板破坏是 Fc 依赖性的。然而，最近的研究也可能表明血小板破坏的 Fc 非依赖性途径的参与。目前的治疗选择通过免疫抑制（例如，皮质类固醇）、免疫调节（例如，IVIg 和抗-D）或去除 ITP 中的血小板破坏部位（脾切除术）来实现。这篇综述将讨论这些治疗方法和其他治疗 ITP 的方法的作用机制。
